Evidence map›Paper›PMID 39380221›Full record

ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2024

Weitiao No. 3 (3) enhances the efficacy of anti-programmed cell death protein-1 immunotherapy by modulating the intestinal microbiota in an orthotopic model of gastric cancer mice.

Huang Xiaona, L I Yuzhen, Zhu Chenyang, Zhu Hengzhou, Jiang Chenyu, Zhu Xiaodan, Zhang Chencen, Jin Chunhui

Abstract read
In one paragraph

Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Huang XiaonaDepartment of Oncology, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine (Wuxi Hospital of Traditional Chinese Medicine), Wuxi 214071, China.
L I YuzhenDepartment of Oncology, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine (Wuxi Hospital of Traditional Chinese Medicine), Wuxi 214071, China.
Zhu ChenyangDepartment of Oncology, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine (Wuxi Hospital of Traditional Chinese Medicine), Wuxi 214071, China.
Zhu HengzhouDepartment of Oncology, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine (Wuxi Hospital of Traditional Chinese Medicine), Wuxi 214071, China.
Jiang ChenyuDepartment of Oncology, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine (Wuxi Hospital of Traditional Chinese Medicine), Wuxi 214071, China.
Zhu XiaodanDepartment of Oncology, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine (Wuxi Hospital of Traditional Chinese Medicine), Wuxi 214071, China.
Zhang ChencenDepartment of Oncology, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine (Wuxi Hospital of Traditional Chinese Medicine), Wuxi 214071, China.
Jin ChunhuiDepartment of Oncology, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine (Wuxi Hospital of Traditional Chinese Medicine), Wuxi 214071, China.

Funding

National Natural Science Foundation of China: to Explore the Role and Mechanism of Weitiao No. 3 in Promoting Immunotherapy of Gastric Cancer by Activating Peroxisome Proliferator-activated Receptor-γ/AMP-activated Protein Kinase Signaling Pathway through Short Chain Fatty Acid based on Intestinal Flora 82274269Nature Foundation of Nanjing University of Chinese Medicine: to Investigate the Effect and Mechanism of Weitiao No. 3 on Immunotherapy of Gastric Cancer based on Peroxisome Proliferator-activated Receptor-γ/AMP-activated Protein Kinase Signaling Pathway XZR2020079Wuxi Administration of Traditional Chinese Medicine Scientific Research Project: Clinical and Basic Study on the Effect of Weitiao No. 3 Mixture on Immunotherapy of Gastric Cancer by Regulating Intestinal Microecology ZYKJ201906
6 · The paper itself

Abstract

objectiveTo explore the effects of Weitiao No. 3 (3, WD-3) on anti-programmed cell death protein-1 (PD-1) immunotherapy in gastric cancer (GC).

methodsThe intestinal microbiota was analyzed by 16S rDNA sequencing of fecal samples from three groups: healthy people (Health), GC patients (GC), and WD-3-treated GC patients (WD-3). Next, we established an orthotopic model of GC mice, which were treated with anti-PD-1, WD-3, or an inoculation of intestinal bacteria. Immune markers CD3, CD4, CD8, and forkhead box protein P3 (FOXP3), and the cell proliferation marker Ki67, were evaluated by immunohistochemistry. Cell apoptosis in GC tumors was assessed by terminal-deoxynucleotidyl-transferase-mediated deoxyuridine triphosphate nick end labeling staining. Enzyme-linked immunosorbent assays (ELISAs) were performed to analyze the serum levels of the following cytokines in GC mice: tumor necrosis factor (TNF)-α, interleukin (IL)-2, IL-6, IL-10, interferon (IFN)-γ, and transforming growth factor (TGF)-β.

resultsSequencing data showed that there were significant differences in the composition of the gut microbial community among the three human groups. The gut bacteria in the three groups mainly comprised the phyla Firmicutes, Proteobacteria, Bacteroidetes, and Actinobacteria. At the genus level, the relative abundances of Bifidobacterium and Coprococcus showed significant decreases in the GC group, and an obvious increase in the WD-3 group, compared with the Health group. Interestingly, the relative abundance of Saccharopolyspora was only detected in the WD-3 group. The results of

conclusionWD-3 enhanced the immunotherapeutic efficacy of anti-PD-1 by modulating the intestinal microbiota in an orthotopic model of GC mice.

Indexed as

Drugs, Chinese HerbalGastrointestinal MicrobiomeImmunotherapyProgrammed Cell Death 1 ReceptorStomach NeoplasmsAnimalsApoptosisCell Line, TumorDisease Models, AnimalFemaleHumansMaleMiceMice, Inbred BALB CDrugs, Chinese HerbalProgrammed Cell Death 1 Receptorgastrointestinal microbiomeimmunotherapyprogrammed cell death 1 receptorstomach neoplasmsWeitiao No. 3

Identifiers

PMID39380221
PMCPMC11462543

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.